{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Locally+Advanced+or+Metastatic+Cancer&page=11", "query": { "condition": "Unresectable Locally Advanced or Metastatic Cancer", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 349, "total_pages": 35, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Locally+Advanced+or+Metastatic+Cancer&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unresectable+Locally+Advanced+or+Metastatic+Cancer&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T11:38:01.892Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04641871", "title": "Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Solid Tumor" ], "interventions": [ { "name": "Sym021", "type": "DRUG" }, { "name": "Sym022", "type": "DRUG" }, { "name": "Sym023", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Symphogen A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2020-10-12", "completion_date": "2024-06-03", "has_results": false, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-11-15T11:38:01.892Z", "location_count": 12, "location_summary": "Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 9 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04641871" }, { "nct_id": "NCT01015833", "title": "Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Adult Hepatocellular Carcinoma", "Recurrent Hepatocellular Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v7", "Stage IIIA Hepatocellular Carcinoma AJCC v7", "Stage IIIB Hepatocellular Carcinoma AJCC v7", "Stage IIIC Hepatocellular Carcinoma AJCC v7", "Stage IV Hepatocellular Carcinoma AJCC v7", "Stage IVA Hepatocellular Carcinoma AJCC v7", "Stage IVB Hepatocellular Carcinoma AJCC v7", "Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacogenomic Study", "type": "OTHER" }, { "name": "Sorafenib Tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 356, "start_date": "2010-02-15", "completion_date": "2018-08-15", "has_results": true, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-11-15T11:38:01.892Z", "location_count": 659, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 404 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Fairbanks", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01015833" }, { "nct_id": "NCT05736731", "title": "A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Solid Tumor", "Pancreatic Cancer", "Pancreatic Neoplasms", "Pancreas Cancer", "Non Small Cell Lung Cancer", "Non Small Cell Lung Cancer Recurrent", "Non-Small Cell Squamous Lung Cancer", "NSCLC", "NSCLC, Recurrent", "Colorectal Cancer", "Colorectal Neoplasms", "Colorectal Adenocarcinoma", "CRC", "Colorectal Cancer Metastatic", "Cancer" ], "interventions": [ { "name": "A2B530", "type": "BIOLOGICAL" }, { "name": "xT-Onco with HLA-LOH Assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DIAGNOSTIC_TEST" ], "sponsor": "A2 Biotherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2023-04-28", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-04-25", "last_synced_at": "2026-11-15T11:38:01.892Z", "location_count": 8, "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 5 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05736731" }, { "nct_id": "NCT04958785", "title": "Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple-Negative Breast Cancer" ], "interventions": [ { "name": "Magrolimab", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2021-12-14", "completion_date": "2024-10-08", "has_results": true, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-11-15T11:38:01.892Z", "location_count": 19, "location_summary": "Phoenix, Arizona • Fresno, California • Fullerton, California + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04958785" }, { "nct_id": "NCT00867321", "title": "Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "sorafenib tosylate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 24, "start_date": "2009-04", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2022-04-19", "last_synced_at": "2026-11-15T11:38:01.892Z", "location_count": 177, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 113 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00867321" }, { "nct_id": "NCT04940299", "title": "Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Locally Advanced Bladder Carcinoma", "Locally Advanced Bladder Urothelial Carcinoma", "Locally Advanced Lung Non-Small Cell Carcinoma", "Locally Advanced Renal Pelvis Carcinoma", "Locally Advanced Renal Pelvis Urothelial Carcinoma", "Locally Advanced Ureter Urothelial Carcinoma", "Locally Advanced Urethral Urothelial Carcinoma", "Malignant Solid Neoplasm", "Metastatic Bladder Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Melanoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Metastatic Urethral Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Stage III Bladder Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Pelvis Cancer AJCC v8", "Stage III Ureter Cancer AJCC v8", "Stage III Urethral Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Bladder Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Lung Cancer AJCC v6", "Stage IV Renal Pelvis Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Unresectable Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2021-09-23", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-11-15T11:38:01.892Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04940299" }, { "nct_id": "NCT05267626", "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Cancer", "Cutaneous Melanoma", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "AU-007", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aulos Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2022-04-04", "completion_date": "2027-02-28", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-11-15T11:38:01.892Z", "location_count": 10, "location_summary": "Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05267626" }, { "nct_id": "NCT02401815", "title": "CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastrointestinal Stromal Tumors" ], "interventions": [ { "name": "CGT9486", "type": "DRUG" }, { "name": "Pexidartinib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cogent Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2015-03-06", "completion_date": "2020-05-11", "has_results": true, "last_update_posted_date": "2025-02-14", "last_synced_at": "2026-11-15T11:38:01.892Z", "location_count": 6, "location_summary": "Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 3 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02401815" }, { "nct_id": "NCT06224673", "title": "ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2 Low Breast Carcinoma", "Triple Negative Breast Cancer", "Hormone-receptor-positive Breast Cancer", "Hormone Receptor Positive Breast Carcinoma" ], "interventions": [ { "name": "ARX788", "type": "DRUG" }, { "name": "Computed Tomography (CT)", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Amiloride", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Laura Huppert, MD, BA", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2026-06-05", "completion_date": "2029-11-30", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-11-15T11:38:01.892Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06224673" }, { "nct_id": "NCT01525069", "title": "Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cholangiocarcinoma", "Liver Neoplasms" ], "interventions": [ { "name": "Floxuridine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2012-04-03", "completion_date": "2022-08-02", "has_results": false, "last_update_posted_date": "2022-08-10", "last_synced_at": "2026-11-15T11:38:01.892Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01525069" } ] }